Lead Product(s) : Clonidine,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioSenic Reacquires Global IP Rights and Provides Update On JTA-004 Development
Details : JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate os...
Product Name : JTA-004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2023
Lead Product(s) : Clonidine,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate os...
Product Name : JTA-004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2023
Lead Product(s) : Clonidine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bone Therapeutics Provides Update on the Progress of Clinical Studies
Details : The JTA-004 Phase III study is a controlled, randomized, double-blind trial. It is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee up to 12 months, compared to placebo or Hylan G-F 20.
Product Name : JTA-004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2021
Lead Product(s) : Clonidine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine,Fast Acting Analgesic,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Financing
Bone Therapeutics Secures Up to €16 Million Loan Financing from the European Investment Bank
Details : EIB financing will support and prepare Bone Therapeutics’ lead asset, the enhanced viscosupplement JTA-004, being evaluated in a registrational phase III clinical trial for the treatment of osteoarthritic pain in the knee, for future regulatory approva...
Product Name : JTA-004
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 07, 2021
Lead Product(s) : Clonidine,Fast Acting Analgesic,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : European Investment Bank
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Clonidine
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JTA-004 is unique patented mix of plasma proteins, hyaluronic acid, and a fast-acting analgesic. Bone Therapeutics has completed recruitment and treated all patients in its pivotal Phase III clinical study with the improved viscosupplement in patients wi...
Product Name : JTA-004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2020
Lead Product(s) : Clonidine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The JTA-004 Phase III study is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20, the leading current osteoarthritis treatment on the market.
Product Name : JTA-004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2020
Lead Product(s) : Clonidine
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clonidine,Fast Acting Analgesic,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $1.1 million
Deal Type : Funding
Details : Funding will provide further financial support to Bone Therapeutics, in addition to recent financing, to advance its current pivotal phase III clinical study with the enriched protein solution, JTA-004.
Product Name : JTA-004
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 13, 2020
Lead Product(s) : Clonidine,Fast Acting Analgesic,Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $1.1 million
Deal Type : Funding
Lead Product(s) : Hyaluronic Acid,Undisclosed
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bone Therapeutics Treats First Patients in Pivotal JTA-004 Phase III Knee Osteoarthritis Study
Details : The JTA-004 phase III study is a controlled, randomized, double-blind trial that will evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2020
Lead Product(s) : Hyaluronic Acid,Undisclosed
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable